ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • 2026 ACR/ARP PRSYM
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Disease Activity"

  • Abstract Number: 0803 • ACR Convergence 2025

    Improved Efficacy and Safety Outcomes in Patients with SLE Treated with Belimumab (BEL) Versus Immunosuppressants (IS), in Addition to Antimalarials (AM) and Glucocorticoids (GC): A Post Hoc Summary of Five Phase 3 Trials

    Mariele Gatto1, Karen H. Costenbader2, Andreas Schwarting3, Julia Harris4, Ciara O'Shea5, Roger A. Levy6 and Andrea Doria7, 1Academic Rheumatology Centre, Department of Clinical and Biological Sciences, University of Turin, Mauriziano Hospital, Turin, Italy, 2Harvard Medical School and Brigham and Women's Hospital, Boston, MA, 3Johannes Gutenberg University Mainz, University Medical Centre, Mainz, Germany, 4GSK, Biostatistics, London, United Kingdom, 5Global Medical Affairs, GSK, Dublin, Ireland, 6GSK, Specialty Care, Global Medical Affairs, Collegeville, PA, 7University of Padova, Padova, Italy

    Background/Purpose: Chronic GC and IS use increases damage accrual and mortality. The 2023 EULAR SLE recommendations support initiation of biologics such as BEL, a human…
  • Abstract Number: 1081 • ACR Convergence 2025

    Insurance, Gender, and COVID-19’s Effects on Health Inequity in Rheumatoid Arthritis: A 12-Year Long Population Assessment

    Ramsha Riaz1, Lifang Zhang2, Andrea Berger2, Hema Srinivasan2, Lisa Schroeder3 and Jonida Cote4, 1Geisinger Medical Center, Danville, PA, 2Geisinger Health System, Danville, PA, 3Geisinger, Danville, PA, 4Geisinger Health System, Wilkes-Barre, PA

    Background/Purpose: Recognizing health care disparities in Rheumatoid Arthritis is crucial to improving outcomes. This study analyzes factors contributing to RA care inequities.Methods: We examined RA…
  • Abstract Number: 1357 • ACR Convergence 2025

    Measuring Rheumatoid Arthritis Outcomes Using Machine Learning Imputed Disease Activity Scores

    Jue Hou1, Feiqing Huang2, Gregory McDermott3, Jun Wen4, Mary Jeffway3, Ying Qi5, Yunqing Han3, Tianrun Cai6, Florence Bourgeois4, Katherine Liao7 and Tianxi Cai2, 1University of Minnesota, Minneapolis, MN, 2Harvard T.H. Chan School of Public Health, Boston, 3Brigham and Women's Hospital, Boston, 4Harvard Medical School, Boston, 5Brigham and Women’s Hospital, Boston, 6Brigham and Women's Hospital, Boston, MA, 7Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital, Boston, MA, USA, Boston, MA

    Background/Purpose: Validated rheumatoid arthritis (RA) disease activity measures such as the Disease Activity Score-28 (DAS28) are used in clinical trials but not universally recorded in…
  • Abstract Number: 1499 • ACR Convergence 2025

    Predictors of Proteinuria Flares in Biopsy Positive Lupus Nephritis

    Michelle Petri1, Andrea Fava2, Daniel Goldman1 and Laurence Magder3, 1Johns Hopkins University School of Medicine, Timonium, MD, 2Johns Hopkins University, Baltimore, MD, 3University of Maryland, Baltimore, Baltimore, MD

    Background/Purpose: Over 20% of lupus nephritis (LN) patients progress to end stage kidney disease. One of the most important predictors is renal flare.Methods: The analysis…
  • Abstract Number: 1973 • ACR Convergence 2025

    Evaluating the Impact of Clinical Pharmacist Integration on Patient Care Outcomes in a Private Rheumatology Clinic

    Madana Kamineni1, Janelle Vircks1, Jessica Lynton1, Clarisse Purvis1 and Brittany Panico2, 1Optum, Gilbert, AZ, 2Summit Rheumatology, Gilbert, AZ

    Background/Purpose: Existing data demonstrate that clinical pharmacist integration in rheumatology clinics improves provider satisfaction, patient outcomes, medication adherence, and RAPID-3 (Routine Assessment of Patient Index…
  • Abstract Number: 2292 • ACR Convergence 2025

    Safety and Humoral Response to Recombinant Herpes Zoster Vaccine in immunosuppressed Sjögren’s Disease Patients: Results From a Double-Blinded Placebo-Controlled Study

    Sandra G Pasoto1, Talita Ribeiro2, Nadia Emi Aikawa3, Ana C Medeiros-Ribeiro1, Bruno Borges2, Andre Franco4, Henrique Silva2, Eloisa Bonfa5 and Clovis Artur Silva6, 1Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, 2Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, Brazil, 3Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, São Paulo, Brazil, 4Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Sao Paulo, Brazil, 5Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, 6University of São Paulo, São Paulo, São Paulo, Brazil

    Background/Purpose: Immunosuppressed Sjögren’s disease (SjD) patients are at increased risk of herpes zoster (HZ). Despite this vulnerability, data on safety and immunogenicity of the recombinant…
  • Abstract Number: 2564 • ACR Convergence 2025

    An illustration-based patient-reported outcome measure reveals concealed symptoms in patients with rheumatoid arthritis and the factor contributing to the discrepancy between patient and evaluator global assessments

    Mie Fusama1, Hideko Nakahara2, Megumi Okada3, Kayoko Sakagami4, Ikuyo Noguchi5, Harumi Matsumura6, Hiroaki Ito4, Kosaku Oda5, Yoshitaka Shinto3, Kenshi Higami6, Satomi Higami6 and Tetsuya Tomita7, 1Kansai University of International Studies, Miki, Japan, 2Osaka Yukioka College of Health Science, Ibaraki, Osaka, Japan, 3Shinto Orthopaedics and Rheumatology Clinic, Osaka, Japan, 4Infusion Clinic, Osaka, Japan, 5Oda Orthopedic Surgery Rheumatology Clinic, Nishinomiya, Japan, 6Higami Clinic of Rheumatology and Diabetology, Kashihara, Japan, 7Morinomiya University of Medical Sciences, Osaka, Japan

    Background/Purpose: RA patients frequently encounter challenges in effectively communicating their symptoms to medical professionals. Recently, the “Okomarigoto Sheet” (OS), an illustration-based patient-reported outcome measure for…
  • Abstract Number: 0260 • ACR Convergence 2025

    Development of a Consensus Definition of VEXAS Flare for Use in Clinical Research

    Lachelle D. Weeks1, Danielle Hammond2, Sinisa Savic3, Mael Heiblig4, Onima Chowdhury5, Arsène Mekinian6, Carmelo Gurnari7, Radhakrishanan Ramchandren8, Sophie georgin-Lavialle9, Marcela ferrada10, Sarah A. Buckley11, Bryan G. harder11, Sandra Goble11, David Beck12 and Matthew Koster13, 1Dana Farber Cancer Institute, Boston, MA, 2The University of Texas MD Anderson Cancer Center, Houston, TX, 3University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, 4Lyon-Sud Hospital, Hospices Civils de Lyon, Paris and Université Claude Bernard, Lyon, France, 5Oxford University Hospitals’ NHS Foundation Trust and Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom, 6Department of Internal Medicine, Inflammation-Immunopathology-Biotherapy Department (DMU i3), Saint-Antoine University Hospital, 75012 Paris, France, Paris, France, 7Department of Biomedicine and Prevention, University of Rome Tor Vergata and Translational Hematology and Oncology Research Department, Taussig Cancer Center, Cleveland Clinic, Clevland, OH, Rome, Italy, 8University of Pittsburgh Medical Center, Pittsburgh, PA, 9Sorbonne university, Tenon hospital, DMU3ID, CEREMAIA, ERN RITA, Paris, France, 10University of Maryland, Bethesda, MD, 11Sobi Inc., Waltham, MA, 12Center for Human Genetics and Genomics, NYU Grossman School of Medicine. Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine. Department of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, NY, USA, New York, NY, 13Mayo Clinic, Rochester, MN

    Background/Purpose: VEXAS syndrome is a recently identified, severe systemic hemato-inflammatory disease with a complex and heterogeneous clinical presentation. The disease is associated with significant morbidity…
  • Abstract Number: 0451 • ACR Convergence 2025

    Menopause Status and Disease Activity in Rheumatoid Arthritis

    Katherine Bracamontes1, David Kellner2, Lucia Chen3, David Elashoff4, Jenny Brook5 and Veena Ranganath2, 1Division of Internal Medicine, UCLA, Los Angeles, CA, 2UCLA, Los Angeles, CA, 3UCLA, Division of General Internal Medicine and Health Services Research, Los Angeles, CA, 4UCLA, Division of General Internal Medicine and Health Services Research, Los Angeles, 5UCLA, Division of General Internal Medicine and Health Services Research, Los Angeles, CA

    Background/Purpose: In women, rheumatoid arthritis (RA) commonly presents around menopause, a timing thought to be influenced by the decline of estrogen and progesterone. However, the…
  • Abstract Number: 0805 • ACR Convergence 2025

    Safety and Efficacy of Hydroxychloroquine According to Weight-based Dose: Results of a Global Systematic Review and Meta-analysis

    Jacquelyn Nestor1, Zahraa Qamhieh2, Shivani Garg3 and April Jorge1, 1Massachusetts General Hospital, Boston, MA, 2University of Wisconsin, Madison, Department of Medicine, Madison, WI, 3University of Madison, School of Medicine and Public Health, Madison, WI

    Background/Purpose: Hydroxychloroquine (HCQ) is a foundational therapy in systemic lupus erythematosus (SLE) treatment, as it prolongs disease-free and damage-free survival. However, the optimal dose is…
  • Abstract Number: 1103 • ACR Convergence 2025

    Validation of the Health Assessment Questionnaire Disability Index in Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis

    Kayla Chubbs1, Carrie Ye2, Shahin Jamal3, Marie Hudson4, Janet Pope5, Tom Appleton6, Sabrina Hoa7, Alexandra Saltman8, Megan Himmel8, Nancy Maltez9, Faiza Khokhar10, Alexandra Ladouceur11, Ines Colmegna12, May Choi13, Manar Elsayed2 and Janet Roberts1, 1Dalhousie University, Halifax, NS, Canada, 2University of Alberta, Edmonton, AB, Canada, 3University of British Columbia, Vancouver, BC, Canada, 4McGill University, Montréal, QC, Canada, 5University of Western Ontario, London, ON, Canada, 6Western University, London, ON, Canada, 7University of Montreal, Brossard, QC, Canada, 8University of Toronto, Toronto, ON, Canada, 9Department of Medicine, Division of Rheumatology, The Ottawa Hospital, University of Ottawa, Ottawa, Canada., Ottawa, ON, Canada, 10Hamilton Ontario, Hamilton, ON, Canada, 11University of Montreal, Montreal, QC, Canada, 12The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, 13University of Calgary, Calgary, AB, Canada

    Background/Purpose: The use of immune checkpoint inhibitors (ICI) continues to increase with an expanding number of indications across varying cancer types and stages. ICIs can…
  • Abstract Number: 1364 • ACR Convergence 2025

    Efficacy Of Ayurvedic Treatment Versus Placebo, Each In Combination With Methotrexate In Early RA Over 20 Weeks: An Exploratory Randomized Control Trial

    Prativa Priyadarshani Sethi1, Venkatesh Srinivasa Pai2, Rajat Ranka2, Avneet Kumar Gupta3, Ashish Baweja4, ritu sangwan5, Abhishek Rai6, Sryla Punjadath1 and Nithya Maskani2, 1All India Institute of Medical Sciences, Rishikesh, Rishikesh, Uttarakhand, India, 2AIIMS RISHIKESH, Rishikesh, Uttarakhand, India, 3AIIMS RISHIKESH, Lucknow, Uttar Pradesh, India, 4Medanta, The Medicity, Gurugram, New Delhi, Delhi, India, 5AIIMS ,Rishikesh, Rishikesh, Uttarakhand, India, 6AIIMS ,RISHIKESH, Bhilai, Chhattisgarh, India

    Background/Purpose: Early rheumatoid arthritis (RA) is a critical therapeutic window where prompt treatment targeting remission or low disease activity can significantly reduce long-term disability and…
  • Abstract Number: 1503 • ACR Convergence 2025

    Lupus Disease Activity Adversely Affects the Quality of Life but not Intimate Relationship and Sexual Function in Indian Female Lupus Patients

    Ranjan Gupta, Nilanchali Singh, Nisha Jawaliya, Rudra Prosad Goswami, Soniya Dhiman and Parul baisoya, All India Institute of Medical Sciences, New Delhi, Delhi, India

    Background/Purpose: Systemic Lupus Erythematosus (SLE) disease activity can affect the normal functioning of the patients. This functioning in various domains can be assessed using quality…
  • Abstract Number: 2058 • ACR Convergence 2025

    Organ-specific disease activity and serological patterns in idiopathic inflammatory myopathies: A descriptive study in a Hispanic cohort

    valeria cantu1, Emmanuel Dominguez-Chapa2, Rebeca L. Polina-Lugo1, Ana Cecilia Bardan Inchaustegui3, fernanda m. garcia-Carrillo4, Ericka S. Reyna-Hernandez5, Daniela A. Mejia-Rodriguez5, Rosa Arvizu-Rivera6, Jesus Alberto Cardenas-de la Garza7, Miguel Villarreal-Alarcón8 and Dionicio A. Galarza-Delgado9, 1Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, 2Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, 3Universidad Autónoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, 4Hospital Universitario "Dr. José Eleuterio González" UANL, Monterrey, Nuevo Leon, Mexico, 5Rheumatology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico, 6Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Nuevo León, Mexico, 7Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México, Monterrey, Mexico, 8Hospital Universitario UANL, Monterrey, Nuevo León, Mexico, 9Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico

    Background/Purpose: Idiopathic inflammatory myopathies (IIM) are rare diseases that involve chronic muscle inflammation, weakness, and pain. Autoantibodies in IIM play a central role in disease…
  • Abstract Number: 2295 • ACR Convergence 2025

    Autoantibody Profiles and Their Association with Organ Involvement in Primary Sjögren’s Syndrome: Insights from ESSDAI

    Deepak Rath1, Sholen Acharya2 and Dr Alakendu Ghosh3, 1John H Stroger Hospital Jr of Cook County, Chicago, Illinois, USA, 60612, Chicago, IL, 2Department of Reproductive Medicine and Surgery, Government Medical College Thiruvananthapuram, Kerala, India, 695004, Chicago, IL, 3Self employed, Kolkata, West Bengal, India

    Background/Purpose: To evaluate the clinical manifestations, systemic disease activity, and serological profile of patients of Primary Sjögren’s syndrome, and to assess associations between specific autoantibodies…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 112
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology